Cowen Raises Price Target on Aquinox Pharma (AQXP) Following R&D Day
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Leerink Partners Remains Bullish on Aquinox Pharma (AQXP) Following Investor Day
October 8, 2015 8:32 AM EDTLeerink Partners reiterated an Outperform rating and $26.00 price target on Aquinox Pharmaceutical (NASDAQ: AQXP) after attending an investor day. At the event, the company unveiled the AQX-1125 Bladder Pain Syndrome/Interstitial Cystitis (BPS/IC) Phase III design it plans propose to FDA at its endof-Phase II meeting in 4Q15.
Analyst Paul Matteis commented,... More
